Europe Cancer Biomarkers Market - Growth, Trends and Forecasts

  • ID: 4387339
  • Report
  • Region: Europe
  • 134 pages
  • Mordor Intelligence
1 of 4
Biomarkers are chemical, physical or biological parameters which can be used to indicate disease states. Oncology biomarkers offers high speed, non invasive cancer diagnosis and believe to enhance cancer detection and screening.

Major factors for the Europe biomarkers market are streamlined drug delivery process, noninvasive technology, increased rates of survival. Increase boost in government and private funding for oncology also fuels the market growth. Market is constrained by high cost of diagnosis, issues related to reimbursement and some of the regulatory policies which hinder the market growth. Government agencies such as Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have taken an active interest in the field.

European biomarkers market is segmented based on type of applications, By services. Global Cancer Biomarker market is segmented based on Cancer biomarker discovery market , and cancer biomarker diagnostic market.

Major companies covered in this market are Roche Diagnostics Limited (Switzerland),GlaxoSmithKline, Plc. (U.K.),Siemens Healthcare (Germany),Epigenomics AG (Germany).

Companies Featured

1) Roche Applied Science

2) Bio-Rad

3) Qiagen

What makes our report Unique?

1) A wide and in depth analysis of various applications, and services provided in Global Biomarker market as well as cancer biomarker market.

2) We provide longest possible market segmentation based on the type of cancers, applications of biomarkers( Risk assessment, disease diagnosis, drug formulation, forensic application) Services( Sample preparation, Assay development, biomarkers validation and testing)

3) We provide you a complete competitive landscape which includes major players in the market, mergers and acquisitions, Collaborations and new product launches.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. INTRODUCTION
1.1 Objective
1.2 Key findings and observations
1.3 Research methodology
1.4 Market stakeholders
2. EXECUTIVE SUMMARY
3. MARKET OVERVIEW
3.1 Definition of the market
3.2 Market growth estimation
3.3 Market size estimation
3.4 Classification of Cancer biomakers
3.5 Technologies used in Identifying cancer biomakers
4. Market Dynamics
4.1 Market Drivers
4.1.1 Non invasive technologies
4.1.2 Increased survival rates
4.1.3 Enhanced accuracy and Speed of diagnosis
4.1.4 Streamlined drug delivery process
4.1.5 Helps in FDA approval of drugs
4.1.6 Boost in government and Private funds for biomarkers discovery
4.2 Market Restraints
4.2.1 High cost of diagnosis
4.2.2 Reimbursement issues
4.2.3 Need for immediate processing
5. Biomarkers Indication Market
5.1 Oncology Biomarkers Market
5.2 Cardiology biomarkers market
5.3 Neurology biomarkers market
5.4 Others Indication Biomarkers Market
5.5 Disease types
5.6 Renal failure
5.7 Arthritis
5.8 Tuberculosis
5.9 Diabetes
6. Europe Biomarkers market segmentation
6.1 Market segmentation, By type of application
6.1.1 Risk Assesment
6.1.2 Development of molecular diagnostics
6.1.3 Disease diagnosis
6.1.4 Drug discovery and development
6.1.5 Drug formulation
6.1.6 Forensic application
6.1.7 Others(DNA fingerprinting and others)
6.2 Market segmentation, By Services
6.2.1 Sample preparation
6.2.2 Assay developement
6.2.3 Biomakers validation and testing
6.3 Market segmentation, By Country
6.3.1 Germany
6.3.2 France
6.3.3 UK
6.3.4 Italy
6.3.5 Spain
6.3.6 Netherlands
6.3.7 Rest of Europe
7. Cancer Biomarkers Market
7.1 Introduction
7.2 Oncology Biomarkers Market
7.3 Oncology biomarkers Discovery market
7.3.1 Genomics
7.3.2 Proteomics
7.3.3 Metabolomics
7.3.4 Transcriptomics
7.3.5 Other Omics
7.3.6 Imaging
7.4 Cancer Biomarkers Diagnostic Market
7.4.1 Immunohistochemical (IHC) tests
7.4.2 Molecular (DNA and genomic) diagnostic assays
7.4.3 Genetic and genomic markers
7.4.5 Proteomics
7.4.6 Flow cytometry
7.4.7 Stem cell markers
7.4.8 Monoclonal antibodies
7.4.9 Pharmacogenomics
7.4.10 DNA microarrays
7.4.11 IVD multivariate index assays (IVDMIA)
8. Competitive Landscape
8.1 Introduction
8.2 New product launches
8.3 Market strategies
8.4 Agreements, Partnerships & expansion
8.5 Mergers and Acquisitions
8.6 Market Share Analysis
9. Key Vendors In Market
9.1 ACE Biosciences A/S (Denmark)
9.1.1 Company overview
9.1.2 Financial overview
9.1.3 Product portfolio
9.1.4 Business strategies
9.1.5 Recent developments
9.2 Affibody AB (Sweden)
9.2.1 Company overview
9.2.2 Financial overview
9.2.3 Product portfolio
9.2.4 Business strategies
9.2.5 Recent developments
9.3 Agendia N.V. (Netherlands)
9.3.1 Company overview
9.3.2 Financial overview
9.3.3 Product portfolio
9.3.4 Business strategies
9.3.5 Recent developments
9.4 Alphalyse A/S (Denmark)
9.4.1 Company overview
9.4.2 Financial overview
9.4.3 Product portfolio
9.4.4 Business strategies
9.4.5 Recent developments
9.5 Ani Biotech Oy (Finland)
9.5.1 Company overview
9.5.2 Financial overview
9.5.3 Product portfolio
9.5.4 Business strategies
9.5.5 Recent developments
9.6 Astrazeneca Plc (United Kingdom)
9.6.1 Company overview
9.6.2 Financial overview
9.6.3 Product portfolio
9.6.4 Business strategies
9.6.5 Recent developments
9.7 Bayer AG (Germany)
9.7.1 Company overview
9.7.2 Financial overview
9.7.3 Product portfolio
9.7.4 Business strategies
9.7.5 Recent developments
9.8 Biocartis SA (Switzerland)
9.8.1 Company overview
9.8.2 Financial overview
9.8.3 Product portfolio
9.8.4 Business strategies
9.8.5 Recent developments
9.9 Biom̩rieux SA (France)
9.9.1 Company overview
9.9.2 Financial overview
9.9.3 Product portfolio
9.9.4 Business strategies
9.9.5 Recent developments
9.10 Biosystems International (France)
9.10.1 Company overview
9.10.2 Financial overview
9.10.3Product portfolio
9.10.4 Business strategies
9.10.5 Recent developments
9.11 Boehringer Ingelheim Gmbh (Germany)
9.11.1 Company overview
9.11.2 Financial overview
9.11.3 Product portfolio
9.11.4 Business strategies
9.11.5 Recent developments
9.12 Dako Denmark A/S (Denmark)
9.12.1 Company overview
9.12.2 Financial overview
9.12.3 Product portfolio
9.12.4 Business strategies
9.12.5 Recent developments
9.13 Decode Genetics (Iceland)
9.13.1 Company overview
9.13.2 Financial overview
9.13.3 Product portfolio
9.13.4 Business strategies
9.13.5 Recent developments
9.14 Epigenomics AG (Germany)
9.14.1 Company overview
9.14.2 Financial overview
9.14.3 Product portfolio
9.14.4 Business strategies
9.14.5 Recent developments
9.15 F. Hoffmann-La Roche Ltd. (Switzerland)
9.15.1 Company overview
9.15.2 Financial overview
9.15.3 Product portfolio
9.15.4 Business strategies
9.15.5 Recent developments
9.16 GE Healthcare Ltd. (United Kingdom)
9.16.1 Company overview
9.16.2 Financial overview
9.16.3 Product portfolio
9.16.4 Business strategies
9.16.5 Recent developments
9.17 Genedata AG (Switzerland)
9.17.1 Company overview
9.17.2 Financial overview
9.17.3 Product portfolio
9.17.4 Business strategies
9.17.5 Recent developments
9.18 Glaxosmithkline, Plc (United Kingdom)
9.18.1 Company overview
9.18.2 Financial overview
9.18.3 Product portfolio
9.18.4 Business strategies
9.18.5 Recent developments
9.19 Novartis AG (Switzerland)
9.19.1 Company overview
9.19.2 Financial overview
9.19.3 Product portfolio
9.19.4 Business strategies
9.19.5 Recent developments
9.20 Pamgene International BV (Netherlands)
9.20.1 Company overview
9.20.2 Financial overview
9.20.3 Product portfolio
9.20.4 Business strategies
9.20.5 Recent developments
9.21 Philips Healthcare (Netherlands)
9.21.1 Company overview
9.21.2 Financial overview
9.21.3 Product portfolio
9.21.4 Business strategies
9.21.5 Recent developments
9.22 Sanofi (France)
9.22.1 Company overview
9.22.2 Financial overview
9.22.3 Product portfolio
9.22.4 Business strategies
9.22.5 Recent developments
9.23 Siemens Healthcare (Germany)
9.23.1 Company overview
9.23.2 Financial overview
9.23.3 Product portfolio
9.23.4 Business strategies
9.23.5 Recent developments
9.24 UCB S.A. (Belgium)
9.24.1 Company overview
9.24.2 Financial overview
9.24.3 Product portfolio
9.24.4 Business strategies
9.24.5 Recent developments
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll